Simvastatin for the Prevention of Exacerbations in Moderate-to-Severe COPD
Author(s) -
Gerard J. Criner,
John E. Connett,
Shawn D. Aaron,
Richard Albert,
William C. Bailey,
Richard Casaburi,
John A. Cooper,
Jeffrey L. Curtis,
Mark T. Dransfield,
MeiLan K. Han,
Barry J. Make,
Nathaniel Marchetti,
Fernando J. Martínez,
Dennis E. Niewoehner,
Paul D. Scanlon,
Frank C. Sciurba,
Steven M. Scharf,
Don D. Sin,
Helen Voelker,
George R. Washko,
Prescott G. Woodruff,
Stephen C. Lazarus
Publication year - 2014
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1403086
Subject(s) - medicine , copd , simvastatin , exacerbation , randomized controlled trial , placebo , diabetes mellitus , vital capacity , physical therapy , lung , diffusing capacity , lung function , alternative medicine , pathology , endocrinology
Retrospective studies have shown that statins decrease the rate and severity of exacerbations, the rate of hospitalization, and mortality in chronic obstructive pulmonary disease (COPD). We prospectively studied the efficacy of simvastatin in preventing exacerbations in a large, multicenter, randomized trial.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom